Risk of hematologic toxicities in patients with solid tumors treated with everolimus: A systematic review and meta-analysis

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 1, 2013, Pages 30-41

  Funakoshi, Tomohiro ^a,c   Latif, Asma ^b,c   Galsky, Matthew D ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Anemia; Everolimus; Hematologic toxicities; Lymphopenia; Meta analysis; Neutropenia; Thrombocytopenia

Indexed keywords

EVEROLIMUS; EXEMESTANE; LETROZOLE; OCTREOTIDE; PLACEBO; TAMOXIFEN;

ANEMIA; ANGIOMYOLIPOMA; BREAST CANCER; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ENDOMETRIUM CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INCIDENCE; KIDNEY CARCINOMA; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; META ANALYSIS; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SOLID TUMOR; STOMACH CANCER; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ANEMIA; EVEROLIMUS; HEMATOLOGIC TOXICITIES; LYMPHOPENIA; META-ANALYSIS; NEUTROPENIA; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; HEMATOLOGIC DISEASES; HUMANS; INCIDENCE; NEOPLASMS; ODDS RATIO; PUBLICATION BIAS; RISK; SIROLIMUS;

EID: 84884152837     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.06.001     Document Type: Review

References (46)

1. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18(16):1926-1945. [Epub 2004/08/18].
2. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006, 6(9):729-734. [Epub 2006/08/18].
3. Motzer R.J., Escudier B., Oudard S., et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116(18):4256-4265. [Epub 2010/06/16].
4. Krueger D.A., Care M.M., Holland K., et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. New Engl J Med 2010, 363(19):1801-1811. [Epub 2010/11/05].
5. Yao J.C., Shah M.H., Ito T., et al. Everolimus for advanced pancreatic neuroendocrine tumors. New Engl J Med 2011, 364(6):514-523. [Epub 2011/02/11].
6. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New Engl J Med 2012, 366(6):520-529. [Epub 2011/12/14].
7. Bissler J.J., Kingswood J.C., Radzikowska E., et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013, [Epub 2013/01/15].
8. Iacovelli R., Palazzo A., Mezi S., Morano F., Naso G., Cortesi E. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncologica 2012, 51(7):873-879. [Epub 2012/08/23].
9. Ramirez-Fort M.K., Case E.C., Rosen A.C., Cerci F.B., Wu S., Lacouture M.E. Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis. Am J Clin Oncol 2012, [Epub 2012/12/18].
10. Gomez-Fernandez C., Garden B.C., Wu S., Feldman D.R., Lacouture M.E. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. Eur J Cancer 2012, 48(3):340-346. [Epub 2011/12/31].
11. Sivendran S., Ying J., Gartrell B.A., et al. Metabolic complications with the use of mTOR inhibitors for cancer therapy: a systematic review and meta-analysis. Genitourinary Cancers Symposium, ASCO 2013, [abstract 398].
12. Novartis Pharma: Afinitor prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf.
13. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J ClinEpidemiol 2009, 62(10):1006-1012. [Epub 2009/07/28].
14. National Cancer Institute: Common Toxicity Criteria version 3. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf.
15. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. Br Med J 2003, 327(7414):557-560. [Epub 2003/09/06].
16. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188. [Epub 1986/09/01].
17. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50(4):1088-1101. [Epub 1994/12/01].
18. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997, 315(7109):629-634. [Epub 1997/10/06].
19. Pavel M.E., Hainsworth J.D., Baudin E., et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011, 378(9808):2005-2012. [Epub 2011/11/29].
20. Baselga J., Semiglazov V., van Dam P., et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27(16):2630-2637. [Epub 2009/04/22].
21. Ellard S.L., Clemons M., Gelmon K.A., et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009, 27(27):4536-4541. [Epub 2009/08/19].
22. Bachelot T., Bourgier C., Cropet C., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012, 30(22):2718-2724. [Epub 2012/05/09].
23. Wolpin B.M., Hezel A.F., Abrams T., et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastaticpancreatic cancer. J Clin Oncol 2009, 27(2):193-198. [Epub 2008/12/03].
24. Amato R.J., Jac J., Giessinger S., Saxena S., Willis J.P. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009, 115(11):2438-2446. [Epub 2009/03/24].
25. Soria J.C., Shepherd F.A., Douillard J.Y., et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. J Clin Oncol 2009, 20(10):1674-1681. [Epub 2009/06/25].
26. Yao J.C., Lombard-Bohas C., Baudin E., et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010, 28(1):69-76. [Epub 2009/11/26].
27. Doi T., Muro K., Boku N., et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010, 28(11):1904-1910. [Epub 2010/03/17].
28. Slomovitz B.M., Lu K.H., Johnston T., et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010, 116(23):5415-5419. [Epub 2010/08/04].
29. Tarhini A., Kotsakis A., Gooding W., et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 2010, 16(23):5900-5907. [Epub 2010/11/04].
30. Seront E., Sautois B., Rottey S., et al. Phase II trial of everolimus monotherapy in the palliative treatment of patients with metastatic transitional cell carcinoma (TCC) after failure of platinum-based therapy: Activity and biomarkers. ASCO Annual Meeting 2011, abstract 4622.
31. Yoon D.H., Ryu M.H., Park Y.S., et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer 2012, 106(6):1039-1044. [Epub 2012/02/22].
32. Varadarajan P., Kotsakis A.P., Martin D., et al. Phase II trial of everolimus in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). ASCO Annual Meeting 2012, (abstract 5541).
33. Sterne J.A., Gavaghan D., Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J ClinEpidemiol 2000, 53(11):1119-1129. [Epub 2000/12/07].
34. Awada A., Cardoso F., Fontaine C., et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008, 44(1):84-91. [Epub 2007/11/28].
35. Novartis Pharma: Zortress prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/zortress.pdf.
36. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl J Med. 2007, 356(22):2271-2281. [Epub 2007/06/01].
37. Gurk-Turner C., Manitpisitkul W., Cooper M. A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. Transplantation 2012, 94(7):659-668. [Epub 2012/09/19].
38. Holdaas H., Rostaing L., Seron D., et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation 2011, 92(4):410-418. [Epub 2011/06/24].
39. Budde K., Becker T., Arns W., et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011, 377(9768):837-847. [Epub 2011/02/22].
40. Vitko S., Margreiter R., Weimar W., et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004, 78(10):1532-1540. [Epub 2004/12/16].
41. De Simone P., Metselaar H.J., Fischer L., et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 2009, 15(10):1262-1269. [Epub 2009/10/01].
42. Gullestad L., Iversen M., Mortensen S.A., et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 2010, 89(7):864-872. [Epub 2010/01/12].
43. Martelli A.M., Evangelisti C., Chiarini F., et al. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochimicaetbiophysicaacta 2010, 1803(9):991-1002. [Epub 2010/04/20].
44. Kalaitzidis D., Sykes S.M., Wang Z., et al. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell 2012, 11(3):429-439. [Epub 2012/09/11].
45. Quesniaux V.F., Wehrli S., Steiner C., et al. The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo. Blood 1994, 84(5):1543-1552. [Epub 1994/09/01].
46. Kaymakcalan M., Je Y., Sonpavde G., et al. Incidence and risk of infections in renal cell cancer (RCC) and non-RCC patients treated with everolimus and temsirolimus: a meta-analysis of randomized control trials. Genitourinary Cancers Symposium ASCO 2013, [abstract 353].